← Back to Search

Behavioural Intervention

Active HD-tDCS plus Speech-Language Therapy for Frontotemporal Dementia

N/A

Recruiting

Led By Kyrana Tsapkini, PhD

Research Sponsored by Johns Hopkins University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 35 weeks

Awards & highlights

Study Summary

This trial will investigate the effects of high definition transcranial direct current stimulation (HD-tDCS) on language abilities in people with primary progressive aphasia (PPA), a neurodegenerative disease that affects language. HD-tDCS will be administered in combination with language therapy, and the effects will be compared to those of language therapy alone.

Who is the study for?

This trial is for right-handed English speakers with a diagnosis of Primary Progressive Aphasia (PPA) or Mild Cognitive Impairment (MCI), specifically those with semantic, non-fluent, logopenic, or unclassifiable PPA. Participants must have at least a 9th grade education and be able to follow directions for baseline tasks.Check my eligibility

What is being tested?

The study tests if high definition transcranial direct current stimulation (HD-tDCS) combined with language therapy improves language abilities in PPA patients more than just language therapy alone. It also examines the long-term effects and changes in brain connectivity through imaging techniques.See study design

What are the potential side effects?

While not explicitly listed here, HD-tDCS can sometimes cause mild side effects like tingling, itching or discomfort at the electrode site on the scalp, headache, fatigue or nausea.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 35 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~35 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 35 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in oral naming (trained items)

Change in oral naming (untrained items)

Change in written naming (trained items)

+1 more

Secondary outcome measures

Change in other language and cognitive task performances (global cognitive changes)

Changes in functional connectivity

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Active HD-tDCS plus Speech-Language TherapyExperimental Treatment1 Intervention

Active HD-tDCS will be applied at the beginning of 45min speech-language therapy session and will last for 20 min.

Group II: Sham plus Speech-Language TherapyPlacebo Group1 Intervention

Sham HD-tDCS will be applied at the beginning of 45min speech-language therapy session.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Institutes of Health (NIH)NIH

2,696 Previous Clinical Trials

6,952,518 Total Patients Enrolled

9 Trials studying Frontotemporal Dementia

3,733 Patients Enrolled for Frontotemporal Dementia

National Institute on Deafness and Other Communication Disorders (NIDCD)NIH

327 Previous Clinical Trials

178,145 Total Patients Enrolled

5 Trials studying Frontotemporal Dementia

539 Patients Enrolled for Frontotemporal Dementia

Johns Hopkins UniversityLead Sponsor

2,256 Previous Clinical Trials

14,820,001 Total Patients Enrolled

10 Trials studying Frontotemporal Dementia

794 Patients Enrolled for Frontotemporal Dementia

Media Library

Speech-Language Therapy (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT02606422 — N/A

Frontotemporal Dementia Research Study Groups: Active HD-tDCS plus Speech-Language Therapy, Sham plus Speech-Language Therapy

Frontotemporal Dementia Clinical Trial 2023: Speech-Language Therapy Highlights & Side Effects. Trial Name: NCT02606422 — N/A

Speech-Language Therapy (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02606422 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the highest population count included in this research endeavor?

"Affirmative. According to clinicaltrials.gov, the trial which was originally posted on April 1st 2013 is actively accepting participants. A total of 70 candidates are required for enrollment at one medical facility."

Answered by AI

Are any fresh entrants currently being accepted for the investigation?

"Affirmative, the clinicaltrial.gov registry confirms that this research effort is still looking for volunteers to join their ranks. It was first listed on April 1st 2013 and it's most recent update happened June 21st 2022. 70 participants are sought from a single trial location."

Answered by AI

Are there any eligibility criteria for participating in this clinical research?

"Eligibility requirements for this medical trial include people with aphasia, primary progressive and an age range of 50 to 90 years old. Approximately 70 participants are being enrolled in the study."

Answered by AI

Does this clinical trial accommodate individuals younger than 75 years old?

"This trial is specifically looking for participants aged 50 to 90. Conversely, 10 trials are available for those younger than 18 and 124 studies cater to individuals 65 or older."

Answered by AI